Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment

Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In t...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hu, Mimi I., Glezerman, Ilya, Leboulleux, Sophie, Insogna, Karl, Gucalp, Rasim, Misiorowski, Waldemar, Yu, Bennett, Ying, Wendy, Jain, Rajul K.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2013
Témata:
Brief Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776443/
https://ncbi.nlm.nih.gov/pubmed/23990665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt225
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky